Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
Efficacy and safety of telaprevir with natural human interferon-[beta] and ribavirin in Japanese chronic hepatitis C patients with depression
Ist Teil von
Hepatology research, 2018-02, Vol.48 (2), p.184
Ort / Verlag
Hoboken: Wiley Subscription Services, Inc
Erscheinungsjahr
2018
Link zum Volltext
Quelle
Wiley Blackwell Single Titles
Beschreibungen/Notizen
Aim To assess the efficacy and safety of telaprevir (TVR) when used in combination with natural human interferon-[beta] (IFN-[beta]) and ribavirin (RBV) for genotype 1 patients with depression compared to IFN-[beta]/RBV therapy in Japan. We also examined the efficacy of the TVR/IFN-[beta]/RBV therapy in treatment failure genotype 2 patients with depression. Methods For the genotype 1 patients, 30 patients received TVR (750 mg every 8 h) for 12 weeks combined with IFN-[beta] and RBV for 24 weeks (Group A), and 30 received IFN-[beta] and RBV for 48 weeks (Group B). For the genotype 2 patients, 14 patients were dosed only with the TVR-based regimen. Results The sustained virologic response (SVR) rates for Group A and Group B were 63.3% and 20.0%, respectively (P=0.001, likelihood ratio test). The SVR rate for genotype 2 patients previously treated with pegylated IFN and/or RBV was 71.4%. No patient dropped out due to exacerbation of depression. The trend of platelet counts after the drugs were given was similar in the TVR/IFN-[beta]/RBV therapy group and the IFN-[beta]/RBV therapy group. Common resistance-associated variants of TVR were identified in 4 of the 13 patients who did not achieve SVR. Conclusion This study showed that an addition of TVR to IFN-[beta]/RBV therapy raised SVR in previously treated and untreated genotype 1 patients and previously treated genotype 2 patients with chronic hepatitis C and depression.